Sun et al. reported that AFP and DCP levels could predict the efficacy of anti-PD-1 immunotherapy in patients with HCC [24], although the PD-1 blockade is a heterogeneous monotherapeutic strategy. The gene discussed is AFP; the disease is hepatocellular carcinoma.